Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | DRD2 | P14416 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761791 | 1.00 | CXCR4 (0.73) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4761788 | 1.00 | CXCR4 (0.73) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4760663 | 0.91 | CXCR4 (0.60) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4759178 | 0.90 | CXCR4 (0.61) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL5052777 | 0.89 | CXCR4 (0.59) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL5052701 | 0.88 | CXCR4 (0.59) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4710952 | 0.86 | CXCR4 (0.54) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL5050916 | 0.85 | CXCR4 (0.73) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL5050907 | 0.85 | CXCR4 (0.73) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL2511898 | 0.85 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730113-B1 | PROCESS FOR THE SYNTHESIS OF A CXCR4 ANTAGONIST | GENZYME CORP (US) | 2016-12-28 | — | — | EP | claimed |
| US-7332605-B2 | Process for the synthesis of CXCR4 antagonist | ANORMED, INC. (CA) | 2008-02-19 | — | — | US | claimed |
| EP-1730113-A1 | PROCESS FOR THE SYNTHESIS OF A CXCR4 ANTAGONIST | ANORMED INC. (CA) | 2006-12-13 | — | — | EP | claimed |
| WO-2005090308-A1 | PROCESS FOR THE SYNTHESIS OF A CXCR4 ANTAGONIST | ANORMED, INC. (CA) | 2005-09-29 | — | — | WO | claimed |
| US-20050209277-A1 | Process for the synthesis of CXCR4 antagonist | ANORMED CORPORATION (CA) | 2005-09-22 | — | — | US | claimed |
| US-7332605-B2 | Process for the synthesis of CXCR4 antagonist | ANORMED, INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| US-7332605-B2 | Process for the synthesis of CXCR4 antagonist | ANORMED, INC. (CA) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209277-A1 | Process for the synthesis of CXCR4 antagonist | CXCR4, CXCR1, CXCL12 | CXCR4 1/4885CHRM2 2228/4885CYP2D6 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.